HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Hiromi Wada Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wada, H. Articles by Hitomi, S. Search for Related Content PubMed PubMed Citation Articles by Wada, H. Articles by Hitomi, S.

Eur J Cardiothorac Surg 1999;15:438-443
© 1999 Elsevier Science NL

Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage I–II NSCLC (non-small cell lung cancer): a randomized clinical trial¹

West Japan Study Group For Lung Cancer Surgery, Department of Thoracic Surgery, Kyoto University, 53 Kawahara-cho, Shougoin, Sakyo-ku, Kyoto, Japan

Received 21 September 1998; received in revised form 14 December 1998; accepted 12 January 1999.

Corresponding author. Tel.: +81-75-751-3837; fax: +81-75-751-4647; e-mail: wada@frontier.kyoto-u.ac.jp

Objective: The West Japan Study Group For Lung Cancer Surgery (WJSG) conducted a randomized controlled trial in order to assess the usefulness of adjuvant chemotherapy for NSCLC. Methods: Patients with completely resected NSCLC (stages I and II) were enrolled in the trial. These patients were randomized into two groups: a surgery alone group; and a chemotherapy group which received intravenous administration of two courses of 4-week PVM chemotherapy (80 mg/m² of Cisplatin on day 1, 2–3 mg/m² of Vindesine on day 1 and/or day 8, and 8 mg/m² of Mitomycin C on day 1), after which they took 400 mg/day of UFT (Uracil+Tegaful) orally for 1 year. Results: Among 229 patients registered for the study from August 1988 to July 1990, 225 were available cases (116 patients in the surgery alone group, and 109 patients in the chemotherapy group). No bias in prognostic factors could be found between the two groups. The 5-year survival rate was 71.1% for the surgery-alone group and 76.8% for the chemotherapy group with no significant difference observed. However, subset analysis demonstrated that PVM therapy improved the post operative survival of pT1N0 patients (the 5-year survival rats: 75.3% for the surgery alone group, and 90.7% for the chemotherapy group P<0.05). Conclusions: It is interesting to find that among pT1N0 patients, who were not regarded as a target of chemotherapy, those receiving chemotherapy showed significantly better prognostic results. These findings suggest the necessity of further studies on the adjuvant chemotherapy, even in the early stages.

Key Words: Early stage • Non-small cell lung cancer • Adjuvant chemotherapy • Uracil+Tegaful • Long-term oral administration

This article has been cited by other articles:

				S. K. Lau, P. C. Boutros, M. Pintilie, F. H. Blackhall, C.-Q. Zhu, D. Strumpf, M. R. Johnston, G. Darling, S. Keshavjee, T. K. Waddell, et al. Three-Gene Prognostic Classifier for Early-Stage Non Small-Cell Lung Cancer J. Clin. Oncol., December 10, 2007; 25(35): 5562 - 5569. [Abstract] [Full Text] [PDF]

				H. Suzuki, S. Ishikawa, H. Satoh, H. Ishikawa, M. Sakai, T. Yamamoto, M. Onizuka, and Y. Sakakibara Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 648 - 652. [Abstract] [Full Text] [PDF]

				D. West, A. J.B. Kirk, and J. Dunning Chemotherapy following complete resection of non-small-cell lung cancer is of small but significant benefit in terms of survival Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 488 - 492. [Abstract] [Full Text] [PDF]

				N. Alam, G. Darling, F. A. Shepherd, J. A. Mackay, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review. Ann. Thorac. Surg., May 1, 2006; 81(5): 1926 - 1936. [Abstract] [Full Text] [PDF]

				E. D. Bernstein, S. M. Herbert, and N. H. Hanna Chemotherapy and Radiotherapy in the Treatment of Resectable Non-Small-Cell Lung Cancer Ann. Surg. Oncol., March 1, 2006; 13(3): 291 - 301. [Abstract] [Full Text] [PDF]

				J. H. Park, C.-T. Lee, H. W. Lee, H. J. Baek, J. I. Zo, and Y. M. Shim Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1086 - 1091. [Abstract] [Full Text] [PDF]

				M. Malet-Martino and R. Martino Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review Oncologist, August 1, 2002; 7(4): 288 - 323. [Abstract] [Full Text] [PDF]

				P. Thomas, C. Doddoli, X. Thirion, O. Ghez, M.-J. Payan-Defais, R. Giudicelli, and P. Fuentes Stage I non-small cell lung cancer: a pragmatic approach to prognosis after complete resection Ann. Thorac. Surg., April 1, 2002; 73(4): 1065 - 1070. [Abstract] [Full Text] [PDF]

				O. Rena, A. Oliaro, A. Cavallo, P. L. Filosso, G. Donati, P. Di Marzio, G. Maggi, and E. Ruffini Stage I non-small cell lung carcinoma: really an early stage? Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 514 - 519. [Abstract] [Full Text] [PDF]

				T. C. Mineo, V. Ambrogi, V. Corsaro, and M. Roselli Postoperative adjuvant therapy for stage IB non-small-cell lung cancer Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 378 - 384. [Abstract] [Full Text] [PDF]

				F. Tanaka, K. Yanagihara, Y. Otake, T. Yamada, T. Shoji, R. Miyahara, K. Inui, and H. Wada Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC) Eur. J. Cardiothorac. Surg., May 1, 2001; 19(5): 555 - 561. [Abstract] [Full Text] [PDF]

				Y. Fujiwara Current Status of Oral Anticancer Drugs in Japan J. Clin. Oncol., October 1, 1999; 17(10): 3362 - 3365. [Full Text] [PDF]